Sonntag, 7. März 2021
Navigation öffnen

FRACTION-GC A Study to Test Combination Treatments in Patients With Advanced Gastric Cancer



November 2016

Letztes Update:

Nivolumab, Ipilimumab, Relatlimab, BMS-986205, Rucaparib

Indikation (Clinical Trials):
Stomach Neoplasms


Erwachsene (18+)

Phase 2

Bristol-Myers Squibb

Clovis Oncology, Inc.


Bristol-Myers Squibb
Study Director
Bristol-Myers Squibb


Recruiting sites have contact information. Please contact the sites directly. If there is no contact information,
Phone: please email:
» Kontaktdaten anzeigen
First line of the email MUST contain NCT# and Site #.

Studienlocations (3 von 45)

Local Institution
V5Z 4E6 Vancouver
CanadaAktiv, nicht rekrutierend» Google-Maps
Sunnybrook Research Institution
M4N 3M5 Toronto,
CanadaAktiv, nicht rekrutierend» Google-Maps
Local Institution
13273 Marseille Cedex 9
FranceZurückgezogen» Google-Maps
Local Institution
34298 Montpellier Cedex 5
FranceZurückgezogen» Google-Maps
Local Institution
08916 Badalona-barcelona
SpainZurückgezogen» Google-Maps
Alle anzeigen


Brief Summary:

The purpose of this study is to determine whether Nivolumab in combination with other therapies is more effective than Nivolumab in combination with Ipilimumab in treating patients/subjects with advanced gastric cancer.


For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit

Inclusion Criteria:

- Advanced Gastric Cancer

- Must have full activity or, if limited, must be able to walk and carry out light activities such as light house work or office work

- Must have at least 1 lesion with measurable disease

- All participants must have inoperable, advanced, or metastatic EC, GC or GEJ carcinoma and have histologically confirmed predominant adenocarcinoma or squamous cell carcinoma. (sub protocol C)

Exclusion Criteria:

- Patients/subjects with HER2 positive tumor that have not been treated with trastuzumab prior to enrollment

- Must not have suspected or known central nervous system metastases unless adequately treated

- Patients/subjects with autoimmune disease

- Patients/subjects who need daily oxygen therapy

- Participants who are considered to be refractory or resistant to platinum agents (sub protocol c)

- Participants who have inability to swallow capsules or pills (sub protocol c)

- Current or recent (within 3 months of study treatment administration) gastrointestinal disease that could interfere with absorption of orally administered systemic treatments (sub protocol c)

- Participants with diagnosis or history of myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML). (sub protocol C)

- Prior treatment with a PARP inhibitor (such as rucaparib, olaparib, niraparib, talozaparib, etc.) or a targeted DNA damage response inhibitor (such as ATM or ataxia telangiectasia and Rad3-related protein [ATR] inhibitor). (sub protocol C)

Other protocol defined inclusion/exclusion criteria could apply


Primary outcome:

1. Objective Response Rate (ORR) (Time Frame - Up to 24 months)

2. Duration of Response (DOR) (Time Frame - Up to 24 months)

3. Progression-free Survival Rate (PFSR) (Time Frame - Up to 24 months)

4. Incidence of Adverse Events (AEs) in Part 1 (Time Frame - Approximately 28 Months)

5. Incidence of Serious Adverse Events in Part 1 (Time Frame - Approximately 28 Months)

6. Incidence of AEs leading to Discontinuation in Part 1 (Time Frame - Approximately 28 Months)

7. Incidence of Deaths in Part 1 (Time Frame - Approximately 28 Months)

8. Incidence of Clinical Laboratory Abnormalities in Part 1 (Time Frame - Approximately 28 Months)

Secondary outcome:

1. Incidence of Adverse Events (AEs) (Time Frame - Approximately 28 months)

2. Incidence of Serious Adverse Events (SAEs) (Time Frame - Approximately 28 months)

3. Incidence of AEs leading to discontinuation (Time Frame - Approximately 28 months)

4. Incidence of AEs leading to death (Time Frame - Approximately 28 months)

5. Incidence of Clinical laboratory test abnormalities (Time Frame - Approximately 28 Months)


  • Active Comparator: Nivolumab (nivo) and Ipilimumab (ipi) Combination
  • Experimental: nivo and Relatlimab Combination
  • Experimental: nivo and BMS-986205 Combination
  • Experimental: Nivo and rucaparib Combination
  • Experimental: Ipi with rucaparib Combination
  • Experimental: nivo with ipi and rucaparib

Geprüfte Regime

  • Nivolumab (Opdivo / BMS-936558 / )
  • Ipilimumab (Yervoy / BMS-734016 / )
  • Relatlimab (BMS-986016)
  • BMS-986205
  • Rucaparib (Rubraca)


Das könnte Sie auch interessieren

Vor der Darmspiegelung ist „Abführen an zwei Tagen“ am effektivsten

Vor der Darmspiegelung ist „Abführen an zwei Tagen“ am effektivsten
© Sebastian Kaulitzki /

Je sauberer der Darm, umso aussagekräftiger ist das Ergebnis einer Darmspiegelung zur Krebsvorsorge. Darauf weisen Experten im Vorfeld des Kongresses Viszeralmedizin 2016 in Hamburg hin. Um den Darm optimal für die „Koloskopie“ vorzubereiten, sollten Patienten auf zwei Tage verteilt eine Poly-Ethylen-Glykol-Lösung (kurz: PEG) als Abführmittel zu sich nehmen, so die Mediziner. Die Darmspiegelung gilt als eines der effektivsten Verfahren der Krebsvorsorge...